Infinity Pharmaceuticals (NASDAQ:INFI) : 9 analysts are covering Infinity Pharmaceuticals (NASDAQ:INFI) and their average rating on the stock is 3, which is read as a Hold. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 9 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Infinity Pharmaceuticals (NASDAQ:INFI) : The consensus price target for Infinity Pharmaceuticals (NASDAQ:INFI) is $1.58 for the short term with a standard deviation of $0.47. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $2, however, the pessimist price target for the company is $1.
Company shares have received an average consensus rating of Hold for the current week Also, In the latest statement by the brokerage house, Morgan Stanley downgrades its outlook on Infinity Pharmaceuticals (NASDAQ:INFI). The current rating of the shares is Equal-weight, according to the research report released by the firm. Previously, the company had a rating of Overweight. The brokerage firm lowers the price target from $11 per share to $1 per share. The rating by the firm was issued on June 15, 2016.
Infinity Pharmaceuticals (NASDAQ:INFI): stock turned positive on Tuesday. Though the stock opened at $1.34, the bulls momentum made the stock top out at $1.36 level for the day. The stock recorded a low of $1.27 and closed the trading day at $1.31, in the green by 0.77%. The total traded volume for the day was 1,313,076. The stock had closed at $1.3 in the previous days trading.
In an insider trading activity,The director officer (President & CEO) of Infinity Pharmaceuticals, Inc., Perkins Adelene Q sold 5,000 shares at $10.93 on June 25, 2015. The Insider selling transaction had a total value worth of $54,650. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.